GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance
Main finding · MACCEResult — go to the resultHazard ratio 0.75 95% CI 0.60–0.93Authors' conclusion
The findings of this cohort study of GLP-1 RA use vs no use in patients with MGUS and diabetes suggest the potential of GLP-1 RA for primary prevention of MACCE. These findings warrant further investigation in prospective randomized trials.
Study context
- Population
- Patients with monoclonal gammopathy of undetermined significance (MGUS) and diabetes diagnosed 2018–2023, without prior heart failure (HF), ischemic heart disease, coronary revascularization, or stroke/TIA460 vs 460 matched
- Participants
- 4,871 patients
- Exposure
- GLP-1 RA use vs no use
- GLP-1 RA usersn = 460
- Nonusersn = 460reference
- Outcome
- Major adverse cardiovascular and cerebrovascular events (MACCE): composite of all-cause mortality, new-onset HF, acute coronary syndrome, and stroke or TIA
- Follow-up
- Up to 5 years from MGUS diagnosis
Methodological detailspropensity score-matched (1:1), TriNetX Global Database
- Propensity score-matched (1:1)
- TriNetX Global Database
Main finding
MACCE
Hazard ratio
0.75
95% CI 0.60–0.93
GLP-1 RA usersvs Nonusers
HR 0.75 (95% CI 0.60–0.93)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
All-cause mortality · up to 5 years
- Significant reduction observed, HR
- 0.57 (0.37-0.87) (95% CI)
- Propensity score-matched
New-onset HF · up to 5 years
- Significant reduction observed, HR
- 0.69 (0.54-0.90) (95% CI)
- Propensity score-matched
Decompensated HF · up to 5 years
- Significant reduction observed, HR
- 0.60 (0.43-0.84) (95% CI)
- Propensity score-matched
Acute kidney injury or end-stage kidney disease · up to 5 years
- Significant reduction observed, HR
- 0.73 (0.57-0.92) (95% CI)
- Propensity score-matched
Original publication
GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance. JAMA Netw Open. Published 2 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →